Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
1,795
Views
3
CrossRef citations to date
0
Altmetric
Neurology
The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis
Carrie M. Hersha Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USACorrespondence[email protected]
, Richard A. Brookb President, Better Health Worldwide, Inc., Newfoundland, NJ, USA
, Ian A. Berenc Integrated Analytics Department, Workpartners LLC, Cheyenne, WY, USA
, Nicholas J. Rohrbackerc Integrated Analytics Department, Workpartners LLC, Cheyenne, WY, USA
, Lori Lebsond Neurology and Immunology, EMD Serono, Inc., One Technology Place, Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany
, Christian Henkee Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany
& Amy L. Phillipsf Health Economics and Outcomes Research, EMD Serono, Inc., One Technology Place, Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany
show all
Pages 479-486
|
Received 11 Jan 2021, Accepted 08 Mar 2021, Published online: 13 Apr 2021
Related Research Data
The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.